MarketCap
Facebook
X
TelegramQuartalsbericht 2026-Q1
hinzugefügt 08.05.2026
Assertio Holdings Betriebsaufwand 2011-2026 | ASRT
Betriebsaufwand Jährlich Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 133 M | 221 M | 229 M | 337 M | 344 M | 355 M | 138 M | 118 M | 115 M | 96.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 355 M | 96.7 M | 209 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 5.87 | 6.53 % | $ 87.2 M |  USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
15.5 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
381 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
80.2 M | $ 2.74 | 0.37 % | $ 1.05 B | Canada |
 |
Harrow Health
HROW
|
174 M | $ 33.0 | 0.12 % | $ 1.21 B | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
519 M | $ 2.66 | - | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 23.35 | -0.55 % | $ 1.08 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.47 | 0.37 % | $ 2 B | Canada |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
1.52 B | $ 5.29 | -3.11 % | $ 3.27 B | Canada |
 |
Solid Biosciences
SLDB
|
179 M | $ 6.62 | 1.85 % | $ 579 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.46 | -2.81 % | $ 190 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.12 | -0.88 % | $ 107 M | Canada |
 |
Evolus
EOLS
|
107 M | $ 6.09 | -5.58 % | $ 393 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.45 | -1.36 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.45 | 0.96 % | $ 433 M | USA |
 |
Veru
VERU
|
35.5 M | $ 2.35 | 5.86 % | $ 34.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
28.9 M | $ 0.76 | -2.32 % | $ 3.06 M | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 7.04 | -2.36 % | $ 278 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 0.73 | 3.0 % | $ 36.5 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
7.68 B | $ 16.65 | 1.15 % | $ 19.4 B | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.79 | -2.06 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
3.11 M | $ 0.76 | -0.29 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
7.41 M | $ 2.12 | 0.47 % | $ 24.5 M | USA |